- 2. (Amended) The pharmaceutical composition according to claim 1, wherein the pharmaceutically tolerable ester of loteprednol is loteprednol etabonate.
- 3. (Amended) The pharmaceutical composition according to claim 1, wherein the β_2 adrenoceptor agonist is selected from the group consisting of salbutamol, reproterol, salmeterol, formoterol and their pharmaceutically tolerable salts.
- 4. (Amended) The pharmaceutical composition according to claim 1, which comprises (i) loteprednol and (ii) formoterol.
- 5. (Amended) The pharmaceutical composition according to claim 1, which comprises (i) loteprednol and (ii) salmeterol.
- 6. (Amended) The pharmaceutical composition according to claim 1, which comprises (i) loteprednol and (ii) reproterol.
- 7. (Amended) A method for the treatment of allergies and/or airway disorders, comprising administering to a patient in need of such treatment an efficacious amount of (i) loteprednol and (ii) at least one β_2 adrenoceptor agonist, if appropriate together with customary excipients or vehicles, for simultaneous, sequential or separate administration.

Page 3

8. (Amended) A process for the preparation of a pharmaceutical composition for the treatment of allergies and/or airway disorders, comprising an effective amount of the active compound loteprednol and at least one β_2 adrenoceptor agonist, wherein loteprednol and the β_2 adrenoceptor agonist or the β_2 adrenoceptor agonists are mixed individually or together, if appropriate together with customary excipients or vehicles, and the mixture thus obtained is converted into suitable administration forms.